Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
March 14, 2008

Lilly Pays $7M Upfront for Transition’s Diabetic Program

  • Transition Therapeutics could reap over $137 million through a collaboration with Eli Lilly covering diabetes compounds. Eli Lilly will initially pay $7 million for the exclusive, worldwide rights to Transition’s gastrin-based therapeutic portfolio.

    The agreement includes TT-223, which is in early clinical development. The candidate is being evaluated in combination with an EGF analogue and a GLP-1 analogue in type 1/2 diabetes as well as metformin in type 2 diabetes. Transition and Lilly will jointly conduct the planned Phase II study in type 2 diabetes. Thereafter, Lilly will be responsible for development and commercialization of all gastrin-based therapeutic products worldwide.

    Gastrin-based therapies provide sustained improvement in glycemic control in preclinical models and early clinical studies, according to the firms.

  • You’re all set! Thank you for subscribing to GEN Highlights.